Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 225.16M P/E - EPS this Y 1.40% Ern Qtrly Grth -
Income -86.93M Forward P/E -4.76 EPS next Y 25.30% 50D Avg Chg -11.00%
Sales 13.91M PEG 0.01 EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 3.47 EPS next 5Y -78.20% 52W High Chg -38.00%
Recommedations 1.80 Quick Ratio 2.10 Shares Outstanding 42.67M 52W Low Chg 166.00%
Insider Own 34.26% ROA -85.72% Shares Float 17.29M Beta 1.47
Inst Own 43.78% ROE -412.98% Shares Shorted/Prior 3.25M/4.19M Price 5.38
Gross Margin -60.48% Profit Margin - Avg. Volume 370,083 Target Price 14.00
Oper. Margin -293.72% Earnings Date Nov 7 Volume 256,755 Change -4.10%
About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Verrica Pharmaceuticals Inc. News
07:30 AM Verrica Announces Pricing of $42.0 Million Public Offering
11/20/24 Verrica Announces Proposed Public Offering
11/04/24 Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
10/24/24 Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
10/09/24 Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...
10/02/24 Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
09/29/24 Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now
09/25/24 Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers?
09/04/24 Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
08/26/24 When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit?
08/15/24 Verrica stock drops after half patients’ tumours gone in skin cancer trial
08/14/24 Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
08/14/24 Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
08/14/24 Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
08/14/24 Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
08/06/24 Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
07/29/24 3 High Insider Ownership US Stocks With Up To 52% Revenue Growth
07/15/24 7 Short-Squeeze Stocks That Could Beat Down the Bears
07/10/24 Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
07/01/24 Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs
VRCA Chatroom

User Image G_33 Posted - 57 minutes from now

$VRCA This offering closes on Monday so there was an obvious demand for this deal. The investors are all over it and the offering got filled. I’d say that’s a very good thing.

User Image hitmongreen Posted - 53 minutes from now

$VRCA what's going on here?

User Image RETAlerts Posted - 3 hours ago

solid 10% gain for $VRCA at 1.012 since it first appeared on our radar. Keep tabs on the RSI and MACD indicators for clues on whether this momentum is sustainable. (15 minute delay)

User Image kharlus Posted - 5 hours ago

$VRCA very toxic financing round … full of warrants .. the float will increase by ~80M shares. I took the loss. Bye and good luck to everyone.

User Image OpenOutcrier Posted - 5 hours ago

$VRCA (-10.1% pre) Verrica Pharmaceuticals Raises $42M Through Public Offering of Shares and Warrants | - Stock Titan https://ooc.bz/l/48949

User Image PopPortfolios Posted - 9 hours ago

$VRCA can anyone explain why offer price and no of shares/warrants offered has been left blank in this sec filling.

User Image G_33 Posted - 20 hours ago

$VRCA Old management screwed things up and were removed. The new management hired Jefferies which is a very good company and is the sole underwriter for the offering. The positive is that the company is restructuring and will survive and progress.

User Image kharlus Posted - 20 hours ago

$VRCA sold … good luck all .

User Image kharlus Posted - 21 hours ago

$VRCA write off … fuck €. Never again. I will stop buying bio

User Image Joesh82 Posted - 21 hours ago

$VRCA Why didn't they try to raise cash while the share price was much higher? The price was over $8 in July, to do an offering now sub $1 at near all time lows is just painful.

User Image Adamseb14 Posted - 1 day ago

$VTGN collecting 100,000 shares by next year, and is nice to be able to buy them cheaply, great opportunity . $VRCA $ARVN $CRMD is you considering a fine stock this is your chance

User Image iaconi Posted - 1 week ago

$VRCA It’s not the end, soon it will be over 1$

User Image G_33 Posted - 1 week ago

$VRCA Someone’s been gobbling up shares fairly aggressively.

User Image Denaciousrajan Posted - 1 week ago

$VRCA any interest in pump and dump?

User Image BioGem Posted - 1 week ago

$VRCA Added to my short on this unwarranted Friday spike. -Cash of 23M in Sep, while current liabilities are -21M and loan is -50M. They have steep losses and a high cash burn rate moving forward. -Per 10-Q filing, cash will last only until Q1 2025 with doubt about going concern statement. -They will be in default on the 'revenue convenant' by December 2024, which accelerates payment of the loan. -Clearly their product has failed at any adoption by doctors, so the imminent solution is to raise equity at a steep discount, with tens of millions of dilutive shares and reverse split or declare bankruptcy.

User Image Neo_Angelo Posted - 1 week ago

$VRCA i remember people were saying this was going to $12......not $0.12

User Image slimfalyfe Posted - 1 week ago

n they say small-caps have no volatility haha 😆 .. growin' up where i'm from it's understood .. just because ya name ain't poppin' doesn't mean moves ain't bein' made ! s/o to the small caps .. we see y'all when they don't 😎 $emkr $mtnb $ogen $vrca n more !

User Image theflynews Posted - 1 week ago

Biotech Alert: Searches spiking for these stocks today - $VRCA - https://thefly.com/permalinks/entry.php/VRCAid4018189

User Image ako13 Posted - 2 weeks ago

$VRCA the only red candle stock today

User Image Fanafjell Posted - 2 weeks ago

$VRCA 0.35 next.

User Image theflynews Posted - 2 weeks ago

Biotech Alert: Searches spiking for these stocks today - $VRCA - https://thefly.com/permalinks/entry.php/VRCAid4016584

User Image Leodus Posted - 2 weeks ago

$VRCA In other recent news, Verrica Pharmaceuticals has finalized two agreements with its former Chief Commercial Officer, Joe Bonaccorso, following his expected departure. The agreements, a Release Agreement and a Consulting Agreement, are set to be included in the company's upcoming Quarterly Report. In financial highlights, Verrica reported strong growth in the second quarter of 2024, with net product revenue reaching $4.9 million, driven primarily by increased demand for YCANTH and an expanded distribution network. Total revenues for the quarter stood at $5.2 million, despite a GAAP net loss of $17.2 million.

User Image Leodus Posted - 2 weeks ago

$VRCA The company, based in West Chester, Pennsylvania, is known for its focus on pharmaceutical preparations, as indicated by its classification under the Standard Industrial Classification code 2834. As of now, Verrica Pharmaceuticals has not named a successor for the CFO position. The transition period until the effective date of Kohler’s resignation is expected to provide the company with some time to manage the change in its executive team. The news of Kohler’s resignation comes during a time of significant attention on executive movements within the pharmaceutical industry, as companies navigate a dynamic healthcare landscape. Verrica Pharmaceuticals, incorporated in Delaware with a fiscal year ending on December 31, is subject to such industry shifts.

User Image Leodus Posted - 2 weeks ago

$VRCA WEST CHESTER, PA – Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced the resignation of its Chief Financial Officer, Terence Kohler, effective October 4, 2024. The announcement, made in a recent SEC filing, states that Kohler is leaving to pursue a new business opportunity. Kohler's departure from the pharmaceutical company was formally communicated to Verrica on September 23, 2024.

User Image whaaatisthisss Posted - 2 weeks ago

$VRCA wow what happened

User Image JohnnyCash777 Posted - 2 weeks ago

$VRCA come see $SGBX

User Image ThisJustin123 Posted - 2 weeks ago

$VRCA Sold for a +6.18% gain. Good luck to all

User Image Adamseb14 Posted - 2 weeks ago

$VTGN Post-election, the government may prioritize mental health policies due to increasing awareness around mental health issues. This can translate into expanded funding for mental health research and faster approval processes for innovative therapies, like those VistaGen is developing. Increased government support would create a favorable backdrop for $VTGN’s growth. $VRCA $CRMD $ARVN

User Image PenkeTrading Posted - 2 weeks ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Verrica Pharmaceuticals Inc. Is that bullish or bearish? $VRCA #Verrica #RsiOversold #NASDAQ

User Image HeresJohnny888 Posted - 2 weeks ago

$VRCA well, fuuuuuck.

Analyst Ratings
RBC Capital Outperform Aug 15, 24
Needham Buy Aug 15, 24
Needham Buy May 16, 24
HC Wainwright & Co. Buy May 14, 24
Needham Buy May 14, 24
Needham Buy Apr 10, 24
Needham Buy Mar 1, 24
HC Wainwright & Co. Buy Mar 1, 24
Jefferies Buy Dec 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Dec 27 Buy 7.17 321,616 2,305,987 7,099,182 12/29/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Dec 21 Buy 6.44 504,652 3,249,959 6,777,566 12/26/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Dec 15 Buy 5.58 1,233,931 6,885,335 6,272,914 12/19/23
Manning Paul B Director Director Jul 24 Buy 5.02 200,000 1,004,000 7,851,128 07/24/23
Hayes Christopher G. Chief Legal Officer Chief Legal Officer Jul 11 Buy 3.40 7,500 25,500 15,714 07/11/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Jul 05 Buy 2.10 1,428,571 2,999,999 5,038,983 07/05/22